Researchers identify strategy to make pediatric bone cancers more vulnerable to immunotherapy

by University of North Carolina at Chapel Hill School of Medicine

edited by Sadie Harley, reviewed by Andrew Zinin

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add to Preferred Sources

Ewing sarcoma is a rare and debilitating type of bone cancer affecting young adults and children. Despite intensive treatment with chemotherapy, surgery and radiation, many children do not overcome the disease.

Pediatric oncologists Ian Davis, M.D., Ph.D., and Justin Sperlazza, M.D., Ph.D., at the UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center are working to expand treatment options and advance studies of pediatric solid tumors with the latest immunotherapies, like chimeric antigen receptor T-cell (CAR T-cell) therapy, which trains a patient's immune system to target and eliminate tumor cells.

In a new paper published in Molecular Cancer Therapeutics, Davis and Sperlazza identified drugs that make Ewing sarcoma cells more vulnerable to CAR T-cell therapy. The preclinical findings could help guide future clinical trials for children and young adults with sarcomas.

"New therapeutic strategies are really needed for patients with bone cancer who either don't respond to upfront therapy or experience relapse of the disease," said Sperlazza, who is first author on the paper. "Now that we know that our strategy works, we believe that we are on the cusp of getting this combination therapy to clinical trials."

Turning on GD2 to expose tumors

Bringing their expertise in gene regulation, Davis and Sperlazza partnered with fellow UNC Lineberger Comprehensive Cancer Center member and pediatric oncologist Barbara Savoldo, M.D., Ph.D. Savoldo has been developing the next generation of CAR T cells that target GD2, a molecule found on the surface of some cancer cells. GD2 acts as a beacon to help immunotherapies recognize and target tumors.

However, researchers needed a way to force GD2 to "turn on" in Ewing sarcoma cells. Sperlazza ran a series of tests with the help of Eshelman School of Pharmacy's Center for Integrative Chemical Biology and Drug Discovery to see what drugs could do the job. They found two drugs with potential: tazemetostat and entinostat.

Davis and Sperlazza then tested the drugs in a preclinical Ewing sarcoma model. They found that combining tazemetostat and entinostat helped GD2-specific CAR T cells more effectively target Ewing sarcoma cells. Notably, more than half of the models that received the combination therapy were disease-free by the end of the study.

Moving toward trials with existing therapies

Following their new findings on CAR T-cell therapy, the Davis lab is focused on seeing if their GD2 strategy is equally effective for other cancer drugs and nonexperimental immunotherapies, like antibody therapies. Davis states that using preexisting therapies will help fast-track their findings to clinical trials and, most importantly, to patients in need.

"For families and kids with Ewing sarcoma, the current treatment is exhausting," said Davis. "It is marked by frequent hospital admissions and clinic visits, as well as significant side effects. We have the opportunity to help improve the lives of these kids with new therapies that minimize toxicity and can improve overall health outcomes."

Publication details

Justin R. Sperlazza et al., GD2 Induction by Combination Chromatin-Directed Inhibitors Enhances Targeting of Ewing Sarcoma and Osteosarcoma by CAR T Cells, Molecular Cancer Therapeutics (2026). DOI: 10.1158/1535-7163.mct-25-0332

Journal information: Molecular Cancer Therapeutics

Key medical concepts

Ewing sarcomaganglioside, GD2entinostattazemetostat

Clinical categories

OncologyPediatricsChildren's health Provided by University of North Carolina at Chapel Hill School of Medicine Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Researchers identify strategy to make pediatric bone cancers more vulnerable to immunotherapy (2026, November 2) retrieved 2 November 2026 from https://medicalxpress.com/news/2026-11-strategy-pediatric-bone-cancers-vulnerable.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.